Richard M. Hoglund

Richard M. Hoglund

Auto-generated profile, based on publicly available information

Richard M. Hoglund

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
NWNicholas J. White
Nicholas J. White
JWJames A. Watson
James A. Watson
RHRichard M. Hoglund
Richard M. Hoglund
XCXin Hui S. Chan
Xin Hui S. Chan
Phaik Yeong CheahPhaik Yeong Cheah
Phaik Yeong Cheah
Joel TarningJoel Tarning
Joel Tarning

15 August 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LSLorenz Von Seidlein
Lorenz Von Seidlein
BHBorimas Hanboonkunupakarn
Borimas Hanboonkunupakarn
PJPodjanee Jittamala
Podjanee Jittamala
PPPongphaya Pongsuwan
Pongphaya Pongsuwan
KCKesinee Chotivanich
Kesinee Chotivanich
SPSasithon Pukrittayakamee
Sasithon Pukrittayakamee
Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,S/AS01 vaccination to the integrated malaria elimination strategy in the Greater Mekong Subregion (GMS), where multidrug-resistant P.falciparum strains have emerged and spread. Prior to evaluating RTS,S/AS01 in large-scale trials we assessed whether the vaccine, administered with and without antimalarial drugs, is safe and immunogenic in Asian populations. Methods: An open-label, randomized, controlled phase 2 trial was conducted in healthy, adult Thai volunteers. Seven vaccine regimens with and without antimalarial drugs (dihydroartemisinin-piperaquine plus a single low dose primaquine) were assessed. Antibody titres against the PfCSP full-length (NANP) 6, PfCSP anti-C–term, PfCSP full-length (N + C-Terminal) were measured by standard enzyme-linked immunosorbent assays. Liquid chromatography was used to measure piperaquine, primaquine and carboxy-primaquine concentrations. Results: 193 volunteers were enrolled and 186 study participants completed the 6 months follow-up period. One month after the last vaccination all study participants had seroconverted to the PfCSP (NANP)6, and the PfCSP Full Length (N + C-Terminal). More than 90% had seroconverted to the Pfanti-C-Term CSP. There was no indication that drug concentrations were influenced by vaccine regimens or the antibody levels by the drug regimens. Adverse events were similarly distributed between the seven treatment groups. No serious adverse events attributable to the study interventions were detected. Conclusion: This study found that RTS,S/AS01 with and without dihydroartemisinin-piperaquine plus a single low dose primaquine was safe and immunogenic in a healthy, adult Asian population.

10 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FAFrauke Assmus
Frauke Assmus
RHRichard M. Hoglund
Richard M. Hoglund
FMFrédéric Monnot
Frédéric Monnot
SSSabine Specht
Sabine Specht
ISIvan Scandale
Ivan Scandale
Joel TarningJoel Tarning
Joel Tarning
Background: To accelerate the progress towards onchocerciasis elimination, a macrofilaricidal drug that kills the adult parasite is urgently needed. Emodepside has shown macrofilaricidal activity against a variety of nematodes and is currently under clinical development for the treatment of onchocerciasis. The aims of this study were i) to characterize the population pharmacokinetic properties of emodepside, ii) to link its exposure to adverse events in healthy volunteers, and iii) to propose an optimized dosing regimen for a planned phase II study in onchocerciasis patients.Methodology / Principal findings: Plasma concentration-time profiles and adverse event data were obtained from 142 subjects enrolled in three phase I studies, including a single-dose, and a multiple-dose, dose-escalation study as well as a relative bioavailability study. Nonlinear mixed-effects modeling was used to evaluate the population pharmacokinetic properties of emodepside. Logistic regression modeling was used to link exposure to drug-related treatment-emergent adverse events (TEAEs). Emodepside pharmacokinetics were well described by a transit-absorption model, followed by a 3-compartment disposition model. Body weight was included as an allometric function and both food and formulation had a significant impact on absorption rate and relative bioavailability. All drug-related TEAEs were transient, and mild or moderate in severity. An increase in peak plasma concentration was associated with an increase in the odds of experiencing a drug-related TEAE of interest.Conclusions/Significance: Pharmacokinetic modeling and simulation was used to derive an optimized, body weight-based dosing regimen, which allows for achievement of extended emodepside exposures above target concentrations while maintaining acceptable tolerability margins.

8 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWThanaporn Wattanakul
Thanaporn Wattanakul
MGMary Ellen Gilder
Mary Ellen Gilder
RMRose McGready
Rose McGready
WHWarunee Hanpithakpong
Warunee Hanpithakpong
NDNicholas P. J. Day
Nicholas P. J. Day
RHRichard M. Hoglund
Richard M. Hoglund
Current guidelines advise against primaquine treatment for breastfeeding mothers to avoid the potential for haemolysis in infants with G6PD deficiency. To predict the haemolytic risk, the amount of drug received from the breast milk and the resulting infant drug exposure need to be characterised. Here, we develop a pharmacokinetic model to describe the drug concentrations in breastfeeding women using venous, capillary, and breast milk data. A mother-to-infant model is developed to mimic the infant feeding pattern and used to predict their drug exposures. Primaquine and carboxyprimaquine exposures in infants are <1% of the exposure in mothers. Therefore, even in infants with the most severe G6PD deficiency variants, it is highly unlikely that standard doses of primaquine (0.25-1 mg base/kg once daily given to the mother for 1-14 days) would cause significant haemolysis. After the neonatal period, primaquine should not be restricted for breastfeeding women (Clinical Trials Registration: NCT01780753).

6 November 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
Palang ChotsiriPalang Chotsiri
Palang Chotsiri
PYPrasert Yodsawat
Prasert Yodsawat
RHRichard M. Hoglund
Richard M. Hoglund
JSJulie A. Simpson
Julie A. Simpson
Joel TarningJoel Tarning
Joel Tarning
The probability of target attainment (PTA) is a common metric in drug dose optimization, but it requires a specific known target concentration threshold. Such target thresholds are not always available for some treatments, and patient and disease groups, particularly when treating children. This study performed pharmacokinetic and pharmacokinetic‐pharmacodynamic (PKPD) simulations to explore different statistical approaches for determining the optimal dose for unknown PK and PKPD targets. To determine an optimal dose, PK and PKPD outcomes in typical patients with a standard adult dosing regimen were simulated and set as the reference profile, and compared to simulated outcomes for different dosing regimens in the population of interest. Statistical distances between the empirical cumulative distribution functions of the outcomes from all possible dosing regimens were calculated and compared to the reference profile. An optimal dose for known PK and PKPD target outcomes was selected to maintain the outcome above the assigned target, while optimal dosing in a population of interest with an unknown target was selected to generate equivalent PK and PKPD outcomes as the typical population. All of the dose optimization methods with commonly used PK and PKPD models and covariates were implemented as an open source freely available Shiny web‐application. The developed pharmacometric method for dose optimization in populations with known and unknown target levels were robust and reproducible, and the implementation of a freely accessible Shiny web‐application ensures widespread use and could be a useful tool for dose optimization in populations of interest.

3 August 2022 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
TWThanaporn Wattanakul
Thanaporn Wattanakul
Palang ChotsiriPalang Chotsiri
Palang Chotsiri
ISIvan Scandale
Ivan Scandale
RHRichard M. Hoglund
Richard M. Hoglund
Joel TarningJoel Tarning
Joel Tarning
Developing and evaluating novel compounds for treatment or prophylaxis of emerging infectious diseases is costly and time-consuming. Repurposing of already available marketed compounds is an appeal...